PharmaLive Analyzes Drugs And Devices In Development For Oncology, The Leading Therapeutic Area Globally
NEWTOWN, Pa., July 12, 2010 –– Canon Data Products Group and PharmaLive.com announce the release of a new Special Report in their therapeutic category series, “Oncology Review and Outlook 2010.” This report provides professionals working in or serving the pharmaceutical, biotechnology, and medical-device industries with analysis of the current oncology market, opportunities for growth, technology advancements, and more.
Cancer is the second-leading cause of death in the United States and the fastest-growing sector of the global pharmaceutical market. The opportunity to improve upon current oncology treatments is significant as these medications are, on average, only 25% effective in the advanced disease setting. The urgent need for effective cancer diagnostics and treatments is forecasted to increase as the population ages. Due to the commercial potential, many major pharmaceutical companies are making significant investments to bolster their pipelines. Presently, more than 800 drugs are under investigation for cancer.
“There were 1.5 million cases of new cancer during 2009 and the estimated yearly costs topped $228 billion,” says Andrew Humphreys, Editor in Chief of Canon Data Products Group. “Roche markets the world’s three best-selling oncology/cancer medicines. Meanwhile, many types and sizes of biopharmaceutical and biotechnology players are developing the next generation of products for this therapeutic area. The industry pipeline contains a huge arsenal of innovative drugs for the oncology setting, representing more than twice the total of any other disease category.”
This PharmaLive Special Report concentrates on the market
leaders for oncology as well as the technologies and products in
development anticipated to lead this disease area in years to come.
This compilation’s prescription-product pipeline details the
following information for each medicine:
• Chemical or substance composition
• Intended indication
• Class of drug
• Clinical status
• Region of development
• Product developer/intended marketer
The pipeline status details preclinical development, Phase I through Phase III, and awaiting approval. Regions of development include the United States, Europe, and Japan. A directory of cancer prescription-drug developers and marketers is included.
Also included in this report is a listing of oncology medical-device entries, sorted by device class, as well as a directory of medical-device companies associated with this disease field.
This PharmaLive Special Report is available at www.PharmaLive.com/specialreports.
For more information, contact Sandra Baker at 215-944-9836 or Sandra.Baker@cancom.com.
About Canon Data Products Group
Canon Data Products Group, a division of Canon Communications LLC,
publishes PharmaLive and Appliance Special Reports, which provide
financial, company, and product statistical data and qualitative
analysis for the global pharmaceutical, biotechnology, medical
device, and appliance industries; maintains eKnowledgeBase, a
comprehensive market intelligence tool serving the pharmaceutical,
biotechnology, and medical-device sectors; and manages company-wide
Site Licenses for PharmaLive.com, Med Ad News, and R&D
Directions.
###
Contact:
Sandra Baker
215-944-9836
Sandra.Baker@cancom.com
Posted: July 2010
